Esperion prices $75M public offering of 30M shares at $2.50 each

Esperion Therapeutics, Inc.

Offering of 30,000,000 shares at $2.50/share; net proceeds ~$70.2M (or ~$80.7M if underwriters' option exercised).
Expected close October 9, 2025; use proceeds for NEXLETOL/NEXLIZET commercialization, R&D, working capital.
Piper Sandler & Cantor Fitzgerald are joint book-running managers; co-managers include Citizens JMP, H.C. Wainwright, Needham.
Shares sold under existing shelf registration statement (File No. 333-286631) effective April 29, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.